Synlogic (SYBX) Competitors $1.48 +0.16 (+11.74%) As of 02:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYBX vs. IFRX, KRON, AVTX, ABVC, CUE, GANX, ATRA, RNXT, RENB, and ZIVOShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include InflaRx (IFRX), Kronos Bio (KRON), Avalo Therapeutics (AVTX), ABVC BioPharma (ABVC), Cue Biopharma (CUE), Gain Therapeutics (GANX), Atara Biotherapeutics (ATRA), RenovoRx (RNXT), Renovaro (RENB), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Its Competitors InflaRx Kronos Bio Avalo Therapeutics ABVC BioPharma Cue Biopharma Gain Therapeutics Atara Biotherapeutics RenovoRx Renovaro ZIVO Bioscience InflaRx (NASDAQ:IFRX) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Is IFRX or SYBX more profitable? Synlogic's return on equity of 10.91% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets InflaRxN/A -64.17% -53.39% Synlogic N/A 10.91%7.47% Which has more risk and volatility, IFRX or SYBX? InflaRx has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Does the media favor IFRX or SYBX? In the previous week, InflaRx had 6 more articles in the media than Synlogic. MarketBeat recorded 7 mentions for InflaRx and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.87 beat InflaRx's score of 0.65 indicating that Synlogic is being referred to more favorably in the news media. Company Overall Sentiment InflaRx Positive Synlogic Very Positive Do insiders and institutionals hold more shares of IFRX or SYBX? 42.4% of InflaRx shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 3.0% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, IFRX or SYBX? Synlogic has lower revenue, but higher earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$129.75K445.48-$49.85M-$0.82-1.05SynlogicN/AN/A-$23.36M-$2.51-0.59 Do analysts prefer IFRX or SYBX? InflaRx presently has a consensus price target of $6.60, suggesting a potential upside of 666.55%. Given InflaRx's stronger consensus rating and higher probable upside, equities research analysts plainly believe InflaRx is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryInflaRx beats Synlogic on 8 of the 14 factors compared between the two stocks. Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.25M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.5920.3828.6319.67Price / SalesN/A304.58439.23185.66Price / CashN/A43.1536.0257.93Price / Book1.357.738.185.64Net Income-$23.36M-$55.11M$3.23B$257.73M7 Day Performance18.95%0.65%-0.20%0.21%1 Month Performance21.90%8.17%5.43%8.47%1 Year Performance-5.45%-2.67%26.39%13.93% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogic1.1411 of 5 stars$1.48+11.7%N/A-14.3%$17.25MN/A-0.5980Positive NewsGap UpHigh Trading VolumeIFRXInflaRx2.7233 of 5 stars$0.82+2.2%$6.60+704.9%-51.0%$53.87M$180K-1.0060Gap UpHigh Trading VolumeKRONKronos Bio2.4278 of 5 stars$0.88+1.5%$1.63+84.7%-38.9%$53.72M$9.85M-0.82100AVTXAvalo Therapeutics3.1189 of 5 stars$4.75-4.2%$30.00+531.6%-60.8%$53.71M$440K0.0040ABVCABVC BioPharma0.3939 of 5 stars$3.99+28.3%N/A+349.6%$52.81M$510K-30.6930News CoverageHigh Trading VolumeCUECue Biopharma4.2071 of 5 stars$0.70+0.7%$3.00+328.4%-24.7%$52.38M$9.29M-1.0560Positive NewsGANXGain Therapeutics2.3554 of 5 stars$1.60-5.3%$8.20+412.5%+36.0%$50.61M$50K-1.8620News CoverageGap DownATRAAtara Biotherapeutics4.4049 of 5 stars$8.58+1.3%$17.75+106.9%-16.9%$50.46M$128.94M-2.31330News CoverageRNXTRenovoRx2.5086 of 5 stars$1.32-2.9%$7.25+449.2%+3.9%$49.74M$240K-3.306RENBRenovaro1.8761 of 5 stars$0.30+2.6%N/A-80.0%$49.72MN/A-0.3920ZIVOZIVO BioscienceN/A$13.00+8.4%N/A+57.0%$49.62M$15.85K-2.6610 Related Companies and Tools Related Companies InflaRx Competitors Kronos Bio Competitors Avalo Therapeutics Competitors ABVC BioPharma Competitors Cue Biopharma Competitors Gain Therapeutics Competitors Atara Biotherapeutics Competitors RenovoRx Competitors Renovaro Competitors ZIVO Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYBX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYBX Stock Alerts